Erratum: Tolerability, efficacy and pharmacokinetics of biculatimde 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration (BJU International (2006) (568) DOI: 10.1111/j.1464-410X.2006.06275.x);Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration

BJU International

Volumn 98, Issue 3, 2006, Pages 563-572

  Tyrrell, Chris J ^a   Iversen, Peter ^b   Tammela, Teuvo ^c   Anderson, John ^d   Björk, Thomas ^e   Kaisary, Amir V ^f   Morris, Thomas ^g  

^a DERRIFORD HOSPITAL   (United Kingdom)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

^d ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

^f ROYAL FREE HOSPITAL   (United Kingdom)

^g ASTRAZENECA   (United Kingdom)

Author keywords

Bicalutamide; Monotherapy; Pharmacokinetics; Prostate cancer; Survival; Tolerability

Indexed keywords

BICALUTAMIDE; ESTRADIOL; LUTEINIZING HORMONE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADVANCED CANCER; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; CANCER SURVIVAL; CANCER THERAPY; CASTRATION; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DEATH; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; ESTRADIOL BLOOD LEVEL; FOLLOW UP; GYNECOMASTIA; HOT FLUSH; HUMAN; HUMAN TISSUE; INSOMNIA; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MASTALGIA; MORBIDITY; PAIN; PHARYNGITIS; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; TESTOSTERONE BLOOD LEVEL; URINARY TRACT INFECTION;

EID: 33746911141     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06455.x     Document Type: Erratum

References (17)

1. Kaisary AV, Tyrrell CJ, Peeling WB, Griffiths K. Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol 1991; 67: 502-8
2. Bolla M, Collette L, Blank L et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360: 103-6
3. Pilepich MV, Winter K, Lawton CA et al. Androgen suppression adjuvant to definitive radiotherapy in carcinomas of the prostate - long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005; 61: 1285-90
4. Iversen P, Tyrrell CJ, Kaisary AV et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol 2000; 164: 1579-82
5. Hedlund PO. Side effects of endocrine treatment and their mechanisms: castration, antiandrogens, and estrogens. Prostate Suppl 2000; 10: 32-7
6. Daniell HW. Osteoporosis due to androgen deprivation therapy in men with prostate cancer. Urology 2001; 58 (Suppl. 2): 101-7
7. Sieber PR, Keiller DL, Kahnoski RJ, Gallo J, McFadden S. Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. J Urol 2004; 171: 2272-6
8. Smith MR, Goode M, Zietman AL, McGovern FJ, Lee H, Finkelstein JS. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Clin Oncol 2004; 22: 2546-53
9. McLeod DG, Iversen P, See WA, Morris T, Armstrong J, Wirth MP; Casodex Early Prostate Cancer Trialists' Group. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 2006; 97: 247-54
10. Tyrrell CJ, Kaisary AV, Iversen P et al. A randomised comparison of 'Casodex'™ (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 1998; 33: 447-56
11. Kaisary AV, Iversen P, Tyrrell CJ, Carroll K, Morris T. Is there a role for antiandrogen monotherapy in patients with metastatic prostate cancer? Prostate Cancer Prostatic Dis 2001; 4: 196-203
12. Tyrrell CJ, Denis L, Newling D, Soloway M, Channer K, Cockshott ID. Casodex™ 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three Phase II dose-ranging studies. Casodex Study Gropu.. Eur Urol 1998; 33: 39-53
13. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41
14. See WA, Wirth MP, McLeod DG et al. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. J Urol 2002; 168: 429-35
15. Garnick MB, Pratt CM, Campion M, Shipley W. The effect of hormonal therapy for prostate cancer on the electrocardiographic QT interval: phase 3 results following treatment with leuprolide and goserelin, alone or with bicalutamide, and the GnRH antagonist abarelix. Proc Am Soc Clin Oncol 2004; 23: 400
16. Lunglmayr G. Efficacy and tolerability of Casodex in patients with advanced prostate cancer. International Casodex Study Group. Anticancer Drugs 1995; 6: 508-13
17. Iversen P, Tyrrell CJ, Kaisary AV et al. Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years. Urology 1998; 51: 389-96